Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia
Open Access
- 4 February 2021
- journal article
- research article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 11 (2), e304
- https://doi.org/10.1002/ctm2.304
Abstract
Background Several genetic alterations have been identified as driver events in chronic lymphocytic leukemia (CLL) pathogenesis and oncogenic evolution. Concurrent driver alterations usually coexist within the same tumoral clone, but how the cooperation of multiple genomic abnormalities contributes to disease progression remains poorly understood. Specifically, the biological and clinical consequences of concurrent high‐risk alterations such as del(11q)/ATM‐mutations and del(17p)/TP53‐mutations have not been established. Methods We integrated next‐generation sequencing (NGS) and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 techniques to characterize the in vitro and in vivo effects of concurrent monoallelic or biallelic ATM and/or TP53 alterations in CLL prognosis, clonal evolution, and therapy response. Results Targeted sequencing analysis of the co‐occurrence of high‐risk alterations in 271 CLLs revealed that biallelic inactivation of both ATM and TP53 was mutually exclusive, whereas monoallelic del(11q) and TP53 alterations significantly co‐occurred in a subset of CLL patients with a highly adverse clinical outcome. We determined the biological effects of combined del(11q), ATM and/or TP53 mutations in CRISPR/Cas9‐edited CLL cell lines. Our results showed that the combination of monoallelic del(11q) and TP53 mutations in CLL cells led to a clonal advantage in vitro and in in vivo clonal competition experiments, whereas CLL cells harboring biallelic ATM and TP53 loss failed to compete in in vivo xenotransplants. Furthermore, we demonstrated that CLL cell lines harboring del(11q) and TP53 mutations show only partial responses to B cell receptor signaling inhibitors, but may potentially benefit from ATR inhibition. Conclusions Our work highlights that combined monoallelic del(11q) and TP53 alterations coordinately contribute to clonal advantage and shorter overall survival in CLL.Keywords
This publication has 50 references indexed in Scilit:
- The role ofATMmutations and 11q deletions in disease progression in chronic lymphocytic leukemiaLeukemia & Lymphoma, 2013
- Biallelic ATM Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 TrialJournal of Clinical Oncology, 2012
- Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemiaHaematologica, 2011
- Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damageBlood, 2009
- Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trialBlood, 2009
- Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancerNature Reviews Molecular Cell Biology, 2008
- Mutation Status of the Residual ATM Allele Is an Important Determinant of the Cellular Response to Chemotherapy and Survival in Patients With Chronic Lymphocytic Leukemia Containing an 11q DeletionJournal of Clinical Oncology, 2007
- Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2005
- Genomic Aberrations and Survival in Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2000
- Irradiation induces G2/M cell cycle arrest and apoptosis in p53-deficient lymphoblastic leukemia cells without affecting Bcl-2 and Bax expressionCell Death & Differentiation, 1998